| Newsflash | ||
|---|---|---|
|
||
| Opiates: Their History and Its Relevance to Today's Treatment |
| Feature Articles - Alternative | |
| Sunday, 31 March 2002 | |
|
Opiates have existed as substances of use and abuse for at least 5,000 years. The Sumerians in Mesopotamia began refining poppies for use in 3400 B.C. Their knowledge and use of the "Hul Gil" or "joy plant" would later be transferred throughout the civilized world.
The Egyptians began an international opium trade around 1300 B.C., spreading the use of opium throughout the Mediterranean region (NIDA, USDHEW, 1978). Pictures of poppies can be found in many ancient Greek, Roman, and Egyptian artifacts. Opium was considered by many to be of divine origin. Alexander the Great later brought opium to Persia and India. By 400 A.D., China was introduced to opium by Arab traders who brought in Egyptian opium. Depending on which source you read, either the Arabs, Turks, or the Portuguese are credited with the introduction of opium smoking about 500 years ago. The Dutch then introduced tobacco and opium smoking to the Chinese. The Chinese used both products separately or in combination.
Kreek and others have pointed out that binge use of opiates leads to a "reset" of the dopamine levels of the brain. There is also the increase of corticotrophin-releasing factor (CRF), a so-called "stress prohormone," which also decreases dopamine and other "good" neurotransmitters. Once reset, there is dysphoria because dopamine levels do not return to their normal baseline. This results in craving or withdrawal. It also prompts continued opiate use to get dopamine levels to pre-use levels. Methadone or L-alpha-acetyl-methadol (LAAM), also a long-acting opiate, are used to stabilize patients by reducing the rapid "ups and downs" of heroin metabolism, decreasing CRF and preventing cravings and withdrawal. Problems associated with methadone use include diversion, side effects of the medicine, stigmatization, access difficulties to get medications every day, and disappointment with the loss of autonomy. There also have been articles regarding methadone's association with domestic violence, although it is not clear as to whether methadone is associated any more with violence than street heroin use (Public Policy of ASAM, 2000). Pain management versus addiction One of the most difficult areas of medical practice deals with the pain management of patients who suffer from chronic, non-malignant pain who are also addicted to opiates. Pain is a subjective response to noxious stimuli, trauma or other disruptions of homeostatic mechanisms of the mind or body. Because it is subjective, only the affected person can report symptoms. Pain in the face of addiction or the possibility of addiction becomes a conundrum for practitioners because of the conflict between attempting to alleviate pain and suffering while trying to do no harm. Ethically, there is no question that pain should be treated adequately. The problem comes in situations where chronic, non-malignant pain is the presenting complaint. Are opiates appropriate in this setting? What should be done for the person who has an addiction? How do we properly train practitioners who under-treat pain and label pseudo-addiction (that is, patients who have medication-seeking behavior because of under-treatment of pain) as addiction? What is to be done to identify addicts who use practitioners as their source of opiates? These are issues of under-treatment of pain by the medical community spurring regulations and standards regarding the use of pain assessment tools, (pain as a "vital sign"). The treatment of pain creates a great deal of ambivalence in healthcare providers as well as a tremendous amount of splitting of emotions between staff, patient, and families. Is it possible to maintain someone with chronic pain on opiates? We know the answer is "yes" for most patients. However, we also know that it is not true for all patients. There is a risk of addiction. Who should take that risk? How are patients properly informed of the risks? Once addiction is known, how is pain best treated? (Heit, 2000). The experts have differing opinions. Future trends There is concern for the current population of opiate dependent people. As a whole, our society and government continue to be misinformed about the plight of those who wish to stop opiate use. For example, at a local hospital, they attempted to get methadone for detoxification of opiate dependent patients. Part of the laws in our state required that we obtain community permission. The community met and a large numbers of residents turned out who knew only that they did not want methadone in their community, period. Later that same year, as Medical Director, I was served notice by the Drug Enforcement Administration that I would lose my DEA registration if buprenorphine were used in our hospital. These stories parallel the early 20th century plight of treatment centers attempting to establish opiate maintenance in the south. Both the government and the population who had never experienced what addiction was like wanted opiates to be eradicated or to go underground. As a treatment community we are not misinformed, yet we are terribly ambivalent about the best way to help this population. If a poll were taken today among individuals who deal professionally with addiction, it would become evident that there would be disparity in treatment strategies for opiate-dependent patients. Who, if any, are methadone candidates? Who should be placed on naltrexone? What is the best way to detoxify this population when they present for treatment? In the case of patients who have chronic pain and are addicted to opiates, how should their pain be managed? Advocacy is the key If history is a good indicator, it is imperative that members of the treatment community continue to advocate for our patients and clients in an ethical manner. This advocacy should include the education of the government, the medical community, as well as the general population regarding:
Joseph A. Troncale, MD, is the Medical Director at the Caron Foundation, a nationally recognized not-for-profit chemically dependency treatment center. Formerly, he was the medical director of the Susquehanna Addictions Center. Dr. Troncale has worked extensively in the medical field for over 15 years and is a Diplomat for the American Board of Family Practice, and a member of the American Society of Addiction Medicine. He is a recipient of the American Medical Association Physician Recognition Award. References Booth, M. (1999). Opium: A History. National Review, Feb. 17. Kasser, C., Geller, A., Howell, E., & Wartenberg, A. (1997). Detoxification: Principles and Protocols. National Institute on Drug Abuse, Vol. 16, Number 4, Chapter 1. Heit, H. A. (April 2000). The American Society of Addiction Medicine, Pain & Addiction: Common Threads, Lecture: Regulatory Issues in Opined Therapy on Non-Malignant Pain. McCoy, A.W. Opium History, 1979 to 1994. Reviewed December 27, 2001 at www.a1b2c3.com/drugs/ Perspectives on the History of Psychoactive Substance Use; NIDA, USDHEW 1978, pp. 134-155. Principles of Addiction Medicine Second Edition, American Society of Addiction Medicine, 1998, Section II, Chapter 4. Public Policy of ASAM, Methadone Treatment; & National Institute on Drug Abuse News Release, March 2000 "New Study Underscores Effectiveness of Methadone Maintenance Treatment for Heroin Addiction." Sullum, J. (1998) Poppycock. National Review, Nov. 9. |
|
| < Prev | Next > |
|---|















